- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03634267
MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA Cervical or Stage II-IVA Vaginal Cancer
MRI Guided Brachytherapy for HPV-Associated Cervical and Vaginal Malignancies
Study Overview
Status
Conditions
- Stage IB2 Cervical Cancer AJCC v8
- Stage II Cervical Cancer AJCC v8
- Stage IIA Cervical Cancer AJCC v8
- Stage IIA1 Cervical Cancer AJCC v8
- Stage IIA2 Cervical Cancer AJCC v8
- Stage IIB Cervical Cancer AJCC v8
- Stage III Cervical Cancer AJCC v8
- Stage IIIA Cervical Cancer AJCC v8
- Stage IIIB Cervical Cancer AJCC v8
- Stage IVA Cervical Cancer AJCC v8
- Stage IVA Vaginal Cancer AJCC v8
- Human Papillomavirus-Related Carcinoma
- Human Papillomavirus-Related Cervical Carcinoma
- Stage II Vaginal Cancer AJCC v8
- Stage IIA Vaginal Cancer AJCC v8
- Stage IIB Vaginal Cancer AJCC v8
- Stage III Vaginal Cancer AJCC v8
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Determine whether MRI guidance during internal radiation therapy applicator placement improves the high-risk clinical target volume (HR-CTV) D90 (dose to 90% of the high-risk clinical target volume) rate compared to conventional guidance, with ultrasound and freehand technique, for patients with cervical and vaginal cancer.
SECONDARY OBJECTIVES:
I. Identify diffusion weighted MRI image features that can be used to identify sites of viable tumor following external beam radiotherapy as assessed by tumor aspirate cytology.
II. Determine if diffusion weighted MRI findings are associated with immune infiltration as assessed by multi-spectral flow cytometry.
III. Identify potential correlates between clinical outcomes (survival, progression) and these data objectives (brachytherapy dosimetry/therapeutic ratio, diffusion-weighted MRI imaging features, tumor aspirate cytology findings).
IV. Define the financial costs and feasibility of an MRI-guided brachytherapy approach to determine the overall healthcare quality value (outcomes/cost) of this novel approach for application at other brachytherapy centers.
OUTLINE:
Participants undergo MRI scan during internal radiation therapy applicator placement.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Ann Klopp
- Phone Number: 713-563-2300
- Email: aklopp@mdanderson.org
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Women with stage 1B2-IVA cervical cancer recommended to receive definitive chemoradiation including brachytherapy; or
- Women with stage II-IVA vaginal cancer recommended to receive definitive chemoradiation including brachytherapy.
Exclusion Criteria:
- Patient or tumor anatomy that requires use of a non-MRI-compatible applicator.
- Patients with implantable cardioverter-defibrillator, pacemaker or other implanted device or medical condition which precludes MRI acquisition.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (MRI, internal radiation therapy)
Participants undergo MRI scan during internal radiation therapy applicator placement.
|
Undergo brachytherapy
Other Names:
Undergo MRI scan
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent of patients achieving high-risk clinical target volume (HR-CTV) dose to 90% (D90)
Time Frame: Up to 4 years
|
Rate will be compared to conventional guidance, with ultrasound and freehand technique.
We will compare the HR-CTV D90 and other secondary dosimetry parameters (e.g.
D2 cc bladder, D2 cc rectum etc.) between the initial scan (subsequent to ultrasound [US] guided or freehand applicator placement) and optimized (with magnetic resonance imaging [MRI] guided placement) treatment plan for each patient using McNemar's test.
|
Up to 4 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: Up to 4 years
|
Up to 4 years
|
|
Diffusion weighted imaging (DWI) outcomes
Time Frame: Up to 4 years
|
Up to 4 years
|
|
Biomarker measurements (tumor viability and tumor T cell profile) from tumor samples
Time Frame: Up to 4 years
|
A paired t-test will be used to compare apparent diffusion coefficient (ADC) areas for each biomarker.
|
Up to 4 years
|
Disease recurrence (local, regional, and distant)
Time Frame: Up to 4 years
|
determined via axial imaging (MRI or PET/CT) on interval follow-up
|
Up to 4 years
|
Progression-free survival
Time Frame: Up to 4 years
|
Up to 4 years
|
|
Incidence and severity of treatment-related toxicities
Time Frame: Up to 4 years
|
as defined via CTCAE v4.0
|
Up to 4 years
|
Cost difference associated with the MRI-guided versus the standard process
Time Frame: Up to 4 years
|
Billing and financial data will be calculated and compared to that of the conventional non-MRI-guided brachytherapy approach.
|
Up to 4 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ann H Klopp, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Vaginal Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Uterine Cervical Neoplasms
- Carcinoma
- Vaginal Neoplasms
Other Study ID Numbers
- 2017-0823 (Other Identifier: M D Anderson Cancer Center)
- P30CA016672 (U.S. NIH Grant/Contract)
- NCI-2018-01569 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stage IB2 Cervical Cancer AJCC v8
-
Ohio State University Comprehensive Cancer CenterRecruitingStage III Uterine Corpus Cancer AJCC v8 | Stage IVA Uterine Corpus Cancer AJCC v8 | Malignant Female Reproductive System Neoplasm | Stage I Cervical Cancer AJCC v8 | Stage IA Cervical Cancer AJCC v8 | Stage IA1 Cervical Cancer AJCC v8 | Stage IA2 Cervical Cancer AJCC v8 | Stage IB Cervical Cancer... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingCervical Intraepithelial Neoplasia | Cervical Adenocarcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Vaginal Adenocarcinoma | Vulvar Intraepithelial Neoplasia | Stage I Cervical Cancer AJCC v8 | Stage IA Cervical Cancer AJCC v8 | Stage IA1 Cervical Cancer AJCC v8 | Stage IA2 Cervical... and other conditionsUnited States
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma | Stage IB2 Cervical Cancer AJCC v8 | Stage II Cervical Cancer AJCC v8 | Stage IIA Cervical Cancer AJCC v8 | Stage IIA1 Cervical Cancer AJCC v8 | Stage IIA2 Cervical Cancer AJCC v8 | Stage IIB Cervical Cancer... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingCervical Large Cell Neuroendocrine Carcinoma | Cervical Neuroendocrine Carcinoma | Cervical Small Cell Carcinoma | Cervical Undifferentiated Carcinoma | Stage I Cervical Cancer AJCC v8 | Stage IA Cervical Cancer AJCC v8 | Stage IA1 Cervical Cancer AJCC v8 | Stage IA2 Cervical Cancer AJCC v8 | Stage... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Prostate Cancer AJCC v8 | Hepatobiliary Neoplasm | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Stage III Uterine Corpus Cancer AJCC v8 | Stage IV Uterine Corpus Cancer AJCC v8 | Stage IVA Uterine Corpus Cancer AJCC v8 | Stage IVB Uterine Corpus Cancer AJCC v8 | Malignant Neoplasm and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedVaginal Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Advanced Cervical Adenocarcinoma | Human Papillomavirus-Related Cervical Squamous Cell Carcinoma | Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma | Stage III Cervical Cancer AJCC v8 | Stage IIIA... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingMalignant Solid Neoplasm | Recurrent Prostate Carcinoma | Localized Prostate Carcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIB Cervical Cancer FIGO 2018 | Stage IIIA Cervical Cancer FIGO 2018 | Stage IIIB Cervical Cancer... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma | Stage IV Uterine Corpus Cancer AJCC v8 | Stage IVA Uterine Corpus Cancer AJCC v8 | Stage IVB Uterine Corpus Cancer AJCC v8 | Recurrent Cervical Carcinoma | Malignant... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
Clinical Trials on Internal Radiation Therapy
-
Center Eugene MarquisCompleted
-
University of UtahRecruitingStage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Endometrial Clear Cell Adenocarcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Serous Adenocarcinoma | Uterine Corpus Sarcoma | Uterine Corpus Carcinosarcoma | Stage IA Uterine Corpus Cancer | Stage IB Uterine Corpus CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma | Cervical Small Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI); Canadian Cancer Trials GroupCompletedAnemia | Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Radiation Toxicity | Cervical Squamous Cell Carcinoma | Drug Toxicity | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical CancerUnited States
-
Leiden UniversityDutch Cancer SocietyCompletedEndometrial CancerNetherlands
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)TerminatedStage II Uterine Corpus Cancer | Endometrial Adenocarcinoma | Stage IA Uterine Corpus Cancer | Stage IB Uterine Corpus Cancer | Stage IIIA Uterine Corpus Cancer | Stage IIIB Uterine Corpus Cancer | Stage IIIC Uterine Corpus Cancer | Stage IVA Uterine Corpus Cancer | Stage IVB Uterine Corpus CancerUnited States
-
Dana-Farber Cancer InstituteCompletedCervical Cancer | Vaginal Cancer | Uterine Cancer | Carcinoma of the VulvaUnited States
-
University of Michigan Rogel Cancer CenterDepartment of Health and Human Services; National Institute for Biomedical...Recruiting
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)TerminatedUterine Corpus Leiomyosarcoma | Stage IIA Uterine Sarcoma | Stage IIB Uterine Sarcoma | Stage IIIA Uterine Sarcoma | Stage IIIB Uterine Sarcoma | Stage IIIC Uterine Sarcoma | Stage IVA Uterine Sarcoma | Stage IVB Uterine Sarcoma | Stage IA Uterine Sarcoma | Stage IB Uterine Sarcoma | Stage IC Uterine SarcomaUnited States
-
Imperial College LondonBiocompatibles UK Ltd, a BT International group companyRecruitingNeuroendocrine Tumors | Liver MetastasesUnited Kingdom